• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

ABIVAX - Articles and news items


Mechanism of action of First-in-class anti-HIV drug, ABX464, published

Industry news / 13 April 2015 / Victoria White

ABIVAX, a biotechnology company developing first-in-class anti-viral drugs and vaccines, has announced publication of the mechanism of action of ABX464…

Abivax logo

ABIVAX signs agreement with the Finlay Institute to commercialise meningococcal and typhoid vaccines in Asia and Latin America

Industry news / 13 November 2014 / ABIVAX

ABIVAX, a leading European, clinical stage biopharmaceutical company developing and commercializing anti-viral compounds and human vaccines, announced that it has signed an agreement with The Finlay Institute, Havana, Cuba…

Abivax logo

ABIVAX strengthens Executive Management team with senior appointments

Industry news / 4 November 2014 / ABIVAX

ABIVAX has appointed Karl Birthistle, M.D., and Daniel Kenny to its Executive Management team as VP of Global Regulatory Affairs and Chief Commercial Officer & VP of Business Development, respectively…